Lorenzo Ruggieri
Overview
Explore the profile of Lorenzo Ruggieri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leone A, Bonadonna S, Cassani C, Barcellini A, Sirico M, Tagliaferri B, et al.
BMJ Oncol
. 2025 Jan;
3(1):e000330.
PMID: 39886120
Transgender and gender-diverse (TGD) individuals face an elevated risk of cancer in comparison with the general population. This increased risk is primarily attributed to an imbalanced exposure to modifiable risk...
2.
Ruggieri L, Amato O, Marrazzo C, Nebuloni M, Dalu D, Cona M, et al.
Int J Mol Sci
. 2025 Jan;
26(1.
PMID: 39796071
In recent years, awareness regarding micro-nanoplastics' (MNPs) potential effects on human health has progressively increased. Despite a large body of evidence regarding the origin and distribution of MNPs in the...
3.
Dalu D, Ridolfo A, Ruggieri L, Cona M, Riva A, De Francesco D, et al.
Vaccines (Basel)
. 2024 Jun;
12(6).
PMID: 38932371
In patients with cancer, tumor- and treatment-induced immunosuppression are responsible for a four-fold increase in morbidity and mortality caused by influenza and invasive infections compared to the general population. The...
4.
Dalu D, Tarkowski M, Ruggieri L, Cona M, Gabrieli A, De Francesco D, et al.
Int J Cancer
. 2023 Dec;
154(8):1371-1376.
PMID: 38100252
Solid cancer patients are at higher risk of SARS-CoV-2 infection and severe complications. Moreover, vaccine-induced antibody response is impaired in patients on anticancer treatment. In this retrospective, observational, hypothesis-generating, cohort...
5.
Cona M, Riva A, Dalu D, Gabrieli A, Fasola C, Lipari G, et al.
Cancer Med
. 2023 Apr;
12(12):12967-12974.
PMID: 37114577
Introduction: Cancer patients are frail individuals, thus the prevention of SARS-CoV-2 infection is essential. To date, vaccination is the most effective tool to prevent COVID-19. In a previous study, we...
6.
Ruggieri L, Moretti A, Berardi R, Cona M, Dalu D, Villa C, et al.
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36902406
A significant proportion of patients treated for early breast cancer develop medium-term and late distant recurrence. The delayed manifestation of metastatic disease is defined as "dormancy". This model describes the...
7.
La Verde N, Riva A, Cona M, Gabrieli A, Cattaneo M, Fasola C, et al.
Int J Cancer
. 2022 Sep;
152(4):661-671.
PMID: 36056571
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of...
8.
Amatu A, Mauri G, Tosi F, Bencardino K, Bonazzina E, Gori V, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267504
Background: oxaliplatin with fluoropyrimidine is a "mainstay" regarding the upfront treatment of metastatic colorectal cancer (mCRC). In contrast, the efficacy and safety of oxaliplatin-based regimens in late-care settings have been...
9.
Pizzutilo E, Pedrani M, Amatu A, Ruggieri L, Lauricella C, Veronese S, et al.
Cancers (Basel)
. 2021 Jun;
13(9).
PMID: 34066817
Background: The potential added value of liquid biopsy (LB) is not well determined in the case of small cell lung cancer (SCLC), an aggressive tumor that can occur either de...
10.
Mauri G, Gori V, Bonazzina E, Amatu A, Tosi F, Bencardino K, et al.
Cancer Treat Rev
. 2020 Oct;
91:102112.
PMID: 33091698
Background: Oxaliplatin represents a main component of cytotoxic treatment regimens in colorectal cancer (CRC). Given its efficacy, oxaliplatin is frequently re-administered in the context of the continuum of care in...